Illumina Gestion

Gestion contrôle des critères 2/4

Le PDG Illumina est Jacob Thaysen, nommé en Sep2023, a un mandat de 1.17 ans. La rémunération annuelle totale est $ 4.69M, composée du salaire de 5.3% et des bonus 94.7%, y compris les actions et options de la société. détient directement 0.006% des actions de la société, d'une valeur de € 1.21M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.2 ans et 6.3 ans.

Informations clés

Jacob Thaysen

Directeur général

US$4.7m

Rémunération totale

Pourcentage du salaire du PDG	5.3%
Durée du mandat du directeur général	1.2yrs
Propriété du PDG	0.006%
Durée moyenne d'occupation des postes de direction	1.2yrs
Durée moyenne du mandat des membres du conseil d'administration	6.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jacob Thaysen a-t-elle évolué par rapport aux bénéfices de Illumina?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 29 2024	n/a	n/a	-US$2b
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$5m	US$250k	-US$1b

Rémunération vs marché: La rémunération totale de Jacob ($USD 4.69M ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 4.81M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Jacob avec les performances de l'entreprise.

PDG

Jacob Thaysen (49 yo)

1.2yrs

Titularisation

US$4,691,233

Compensation

Mr. Jacob Thaysen, Ph.D. serves as Chief Executive Officer at Illumina, Inc. since September 25, 2023 and serves as its Director since September 2023. Mr. Thaysen joined the Illumina, Inc. in September 202...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Jacob Thaysen	CEO & Director	1.2yrs	US$4.69m	0.0056% € 1.2m
Carissa Rollins	Chief Information Officer	2.7yrs	US$2.93m	0.0018% € 382.0k
Charles Dadswell	Advisor	less than a year	US$4.10m	0.0044% € 954.9k
Stephanie Campos	President	no data	pas de données	pas de données
Kevin Pegels	Chief of Global Operations	3yrs	pas de données	0.010% € 2.2m
Scott Ericksen	VP & Chief Accounting Officer	2.1yrs	pas de données	0.0067% € 1.4m
Steven Barnard	Chief Technology Officer	1.3yrs	pas de données	0.017% € 3.7m
Sallilyn Schwartz	Vice President of Investor Relations	3.8yrs	pas de données	pas de données
Scott Davies	Interim General Counsel & Secretary	less than a year	pas de données	0.0084% € 1.8m
Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	less than a year	pas de données	0.0044% € 948.5k
Pat Leckman	Senior VP & Chief People Officer	less than a year	pas de données	0.0099% € 2.1m
Everett Cunningham	Chief Commercial Officer	less than a year	pas de données	0.0029% € 628.7k

1.2yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ILU n'est pas considérée comme expérimentée (ancienneté moyenne 1.2 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jacob Thaysen	CEO & Director	1.2yrs	US$4.69m	0.0056% € 1.2m
Caroline Dorsa	Independent Director	7.8yrs	US$408.88k	0.0062% € 1.3m
Susan Siegel	Independent Director	5.8yrs	US$398.58k	0.0050% € 1.1m
Stephen MacMillan	Independent Chairman of the Board	1.4yrs	US$388.22k	0.00095% € 203.9k
Philip Schiller	Independent Director	8.3yrs	US$395.10k	0.0086% € 1.9m
Robert Epstein	Independent Director	12yrs	US$405.10k	0.0099% € 2.1m
Gary Guthart	Independent Director	6.9yrs	US$404.29k	0.0063% € 1.3m
Scott Ullem	Independent Director	1.4yrs	US$345.03k	0.0013% € 279.0k
Frances Arnold	Independent Director	8.8yrs	US$400.10k	0.0092% € 2.0m
Leslie Biesecker	Member of Ethics Advisory Board	no data	pas de données	pas de données
Scott Gottlieb	Independent Director	4.8yrs	US$391.37k	0.0035% € 753.2k
Clement Adebamowo	Member of Ethics Advisory Board	no data	pas de données	pas de données

6.3yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ILU sont considérés comme expérimentés (ancienneté moyenne 6.3 ans).

Illumina Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Illumina, Inc. Announces Executive Changes

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Announces CEO Changes

Recent updates

Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio

Third quarter 2024 earnings released: EPS: US$4.43 (vs US$4.77 loss in 3Q 2023)

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting

Illumina, Inc. Introduces the MiSeq i100 Series

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Second quarter 2024 earnings released: US$12.50 loss per share (vs US$1.48 loss in 2Q 2023)

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Illumina, Inc. Appoints Anna Richo to its Board of Directors

First quarter 2024 earnings released: US$0.79 loss per share (vs US$0.019 profit in 1Q 2023)

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 21% undervalued after recent price drop

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: US$7.35 loss per share (vs US$28.05 loss in FY 2022)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Now 21% undervalued

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 21% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

New minor risk - Share price stability

Third quarter 2023 earnings released: US$4.77 loss per share (vs US$24.31 loss in 3Q 2022)

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.48 loss per share (vs US$3.41 loss in 2Q 2022)

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

Illumina, Inc. Announces CEO Changes

Illumina, Inc. Announces Board Changes

Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients

Chief Commercial Officer recently sold €966k worth of stock

Illumina, Inc. Announces Board Changes

First quarter 2023 earnings released: EPS: US$0.019 (vs US$0.55 in 1Q 2022)

Full year 2022 earnings released: US$28.05 loss per share (vs US$5.08 profit in FY 2021)

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Illumina Appoints Joydeep Goswami as Chief Financial Officer

Now 21% undervalued after recent price drop

Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Insufficient new directors

Third quarter 2022 earnings released: US$24.31 loss per share (vs US$2.09 profit in 3Q 2021)

Illumina Provides Earnings Guidance for the Full Year of 2022

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022

Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022

Illumina Intends to Appeal EC's Decision in Grail Deal

Second quarter 2022 earnings released: US$3.41 loss per share (vs US$1.27 profit in 2Q 2021)